Merit Medical price target lowered at Raymond James, weakness an opportunity

Raymond James analyst Jayson Bedford lowered the firm’s price target on Merit Medical (MMSI) to $108 from $116 and keeps an Outperform rating on the shares. The weakness in shares following the -8% revision in 2025 EPS guidance is a buying opportunity, the analyst tells investors in a research note. The lower guidance is due to the current tariff policies, but Merit has a line-of-sight into mitigation strategies that should reduce the impact by nearly 50% during 2026, the firm says.